Post by
westcoast1000 on Jul 05, 2023 1:55pm
Perfect arbitrage
The US and Cdn prices for ONCY today are in perfect balance given the exchange rate.
Markets are efficient for that kind of transaction, yet in a global sense, the market for ONCY shares is wildly inefficient relative to the expected value of returns from successful results in pancan, CRC and in mBC.
Sentifment drives share price and we still do not yet have positive sentiment on our side. If we did, we would have a market cap approaching $1 bill or more.
Comment by
fox7mf on Jul 05, 2023 2:51pm
Agreed westcoast. Once we're given the nod for ph3 in PDAC & mBC we should approach a MC of $2.5b usd. My opinion and that of Bay Bridge Bio;) Once we're at that MC, then we can expect/hope for the 150-200% buyout premium!!!!!
Comment by
westcoast1000 on Jul 05, 2023 3:22pm
That is what I would expect with continued trial success, Fox. Conditional on success, I would guess we are worth at least a third of Immunometics, maybe more if we wait longer for more CAR-T, and OS data on panc mBC and maybe CRC. All my own opinion.
Comment by
westcoast1000 on Jul 05, 2023 3:25pm
A final note: as Noteable has shown us many times through the biotech press, the demand side for aquisition of assets by big pharma is on fire, and very well funded. All else equal, those conditions clearly makes an aquisition more likely and richer.